ANTIARRHYTHMIC DRUG CLASSIFICATIONS - A CRITICAL-APPRAISAL OF THEIR HISTORY, PRESENT STATUS, AND CLINICAL RELEVANCE

被引:55
作者
NATTEL, S
机构
[1] MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL H3A 2T5, QUEBEC, CANADA
[2] MCGILL UNIV, DEPT MED, MONTREAL H3A 2T5, QUEBEC, CANADA
关键词
D O I
10.2165/00003495-199141050-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Classification of antiarrhythmic drugs have developed because of a need to organise the large number of agents available according to pharmacological properties of clinical relevance. The current classification is a hybrid of classification systems developed in the early 1970s. It subdivides drugs according to 4 major pharmacological actions: (a) depression of phase 0 sodium current; (b) antagonism of adrenergic effects on the heart; (c) prolongation of action potential duration; and (d) calcium channel blockade. Further subdivision of sodium channel blockers is based on the kinetics of sodium channel blockade and drug effects on action potential duration. A critical analysis of selected aspects of the clinical actions of antiarrhythmic drugs indicates the value of the current classification, as well as some limitations in its ability to separate drugs into distinct groups with characteristic clinical properties. The strengths of the current classification are due to the clinical importance of the pharmacological properties on which it is based. These results in electrophysiological actions, indications, and adverse effects that are typical for each group of drugs. The limitations of the current system relate to the propensity of individual drugs to have actions of more than one class simultaneously, the way that the various actions of a given drug are dependent on concentration, rate, and tissue type, and to problems in subclass definition. Some of these shortcomings could be alleviated by returning to the concept, originally put forward by Singh and Vaughan Williams, of classes of drug action rather than classes of drug per se. This approach would be pharmacologically more realistic than trying to assign each antiarrhythmic agent to a single unique class, would be better able to incorporate the complexities of drug action, and would potentially be more flexible. The wide use of antiarrhythmic drug classifications attests to their value, and suggests that they are likely to continue to be important in the future.
引用
收藏
页码:672 / 701
页数:30
相关论文
共 283 条
  • [1] CLINICAL EFFICACY AND ELECTROPHYSIOLOGIC EFFECTS OF INTRAVENOUS AND ORAL ENCAINIDE IN PATIENTS WITH ACCESSORY ATRIOVENTRICULAR PATHWAYS AND SUPRAVENTRICULAR ARRHYTHMIAS
    ABDOLLAH, H
    BRUGADA, P
    GREEN, M
    WEHR, M
    WELLENS, HJJ
    PAULUSSEN, G
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (06) : 544 - 549
  • [2] ADGEY AAJ, 1969, LANCET, V1, P1169
  • [3] TOCAINIDE FOR DRUG-RESISTANT SUSTAINED VENTRICULAR TACHYARRHYTHMIAS
    ADHAR, GC
    SWERDLOW, CD
    LANCE, BL
    CLAY, D
    BARDY, GH
    GREENE, HL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1988, 11 (01) : 124 - 131
  • [4] LONG-TERM EXPERIENCE WITH SOTALOL IN THE TREATMENT OF COMPLEX VENTRICULAR ARRHYTHMIAS
    ANASTASIOUNANA, MI
    ANDERSON, JL
    ASKINS, JC
    GILBERT, EM
    NANAS, JN
    MENLOVE, RL
    [J]. AMERICAN HEART JOURNAL, 1987, 114 (02) : 288 - 295
  • [5] OCCURRENCE OF EXERCISE-INDUCED AND SPONTANEOUS WIDE COMPLEX TACHYCARDIA DURING THERAPY WITH FLECAINIDE FOR COMPLEX VENTRICULAR ARRHYTHMIAS - A PROBABLE PROARRHYTHMIC EFFECT
    ANASTASIOUNANA, MI
    ANDERSON, JL
    STEWART, JR
    CREVEY, BJ
    YANOWITZ, FG
    LUTZ, JR
    JOHNSON, TA
    [J]. AMERICAN HEART JOURNAL, 1987, 113 (05) : 1071 - 1077
  • [6] ELECTROPHYSIOLOGIC AND ANTI-ARRHYTHMIC EFFECTS OF ORAL FLECAINIDE IN PATIENTS WITH INDUCIBLE VENTRICULAR-TACHYCARDIA
    ANDERSON, JL
    LUTZ, JR
    ALLISON, SB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1983, 2 (01) : 105 - 114
  • [7] MULTICENTER TRIAL OF SOTALOL FOR SUPPRESSION OF FREQUENT, COMPLEX VENTRICULAR ARRHYTHMIAS - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED EVALUATION OF 2 DOSES
    ANDERSON, JL
    ASKINS, JC
    GILBERT, EM
    MILLER, RH
    KEEFE, DL
    SOMBERG, JC
    FREEDMAN, RA
    HAFT, LR
    MASON, JW
    LESSEM, JN
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 8 (04) : 752 - 762
  • [8] CLINICAL ELECTROPHYSIOLOGIC EFFECTS OF TOCAINIDE
    ANDERSON, JL
    MASON, JW
    WINKLE, RA
    MEFFIN, PJ
    FOWLES, RE
    PETERS, F
    HARRISON, DC
    [J]. CIRCULATION, 1978, 57 (04) : 685 - 691
  • [9] ORAL FLECAINIDE ACETATE FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS
    ANDERSON, JL
    STEWART, JR
    PERRY, BA
    VANHAMERSVELD, DD
    JOHNSON, TA
    CONARD, GJ
    CHANG, SF
    KVAM, DC
    PITT, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (09) : 473 - 477
  • [10] [Anonymous], 1989, NEW ENGL J MED, V321, P406